Biotechnology
Price
$216.12
+3.04%Market Cap
$31.91B
Day High
$219.01
Day Low
$210.75
Biogen delivered a solid Q1 2026 with revenue up 1.9% YoY to $2.48B, while net income surged 32.8% to $319.5M and operating cash flow nearly tripled to $645.5M, reflecting improved profitability and working capital management.
Key risk: Rising Cost of Revenue Pressuring Gross Margins
Cost of revenue increased 5.0% YoY to $661.0M, outpacing revenue growth of 1.9%, which compresses gross margins. Sustained cost inflation in manufacturing or royalties could erode profitability if revenue growth does not accelerate.
Other Biotechnology companies